-90%

est. 2Y upside i

HealthcareSeed

We're building fully automated labs for protein engineering

Rank

#2182

Sector

Biotechnology Research

Est. Liquidity

~6Y

Data Quality

Data: Medium

Adaptyv operates in a promising, high-growth ($160.5B TAM, +23% YoY) AI-driven protein engineering market with strong early traction (30+ partners).

Last updated: March 9, 2026

Bull (15%)+350%

Adaptyv's automated cloud lab becomes the industry standard for AI-driven protein validation, securing multiple large-scale partnerships with top-tier pharmaceutical companies. This drives revenue to over $50M within 2-3 years, justifying a Series B/C valuation exceeding $200M, representing a 4.4x return from the current valuation.

Base (40%)+75%

Adaptyv successfully expands its customer base and platform capabilities, establishing itself as a key player in a specialized segment of protein engineering. Revenue grows steadily to $15-20M within 2-3 years, leading to a Series A/B valuation of $75-80M, approximately a 1.7x return from the current valuation.

Bear (45%)-85%

Dominant incumbents or well-funded competitors launch superior or cheaper in-house AI-driven protein validation solutions, commoditizing Adaptyv's offering. Growth stalls, and the company struggles to raise subsequent funding rounds, potentially leading to a down round or acquisition at a valuation below $10M, wiping out most common stock value given the preference stack.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Investors hold $11M in liquidation preferences ahead of common stock, representing 24.4% of the estimated $45M current valuation.

Dilution Risk

high

As a seed-stage company, Adaptyv will require multiple future funding rounds, leading to significant dilution for common stock holders.

Secondary Liquidity

none

There is no active secondary market for Adaptyv's shares at this early stage.

Software & Lab Automation — 2 roles

Wildcard — 1 role

View all 5 open roles at Adaptyv →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Adaptyv's data — designed to show you've done your homework.

  • 1

    “Given the high incumbent threat from large pharma and AI labs, how does Adaptyv plan to differentiate its platform and maintain a competitive edge beyond its current early traction?”

  • 2

    “With $11M in total funding and a high capital intensity business model, what is the company's detailed plan for achieving profitability or securing subsequent funding rounds to avoid significant dilution for early employees?”

  • 3

    “Considering the estimated $45M valuation at the seed stage, what are the key milestones and growth metrics the company aims to achieve within the next 2-3 years to justify a significant step-up in valuation for a potential Series A or B round, and what is the expected timeline for a liquidity event for employees?”

Community

Valuation Sentiment

Our model estimates -90% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.